Related Experiment Video
Updated: Dec 13, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Association of serum VLDL level with hyperhomocysteinemia in hypertensive patients: A cross-sectional study
Insights
High very low-density lipoprotein (VLDL) levels are linked to increased risk of hyperhomocysteinemia (HHcy) in hypertensive patients. This association is independent of other risk factors, suggesting VLDL as a potential indicator for this condition.
Area of Science:
- Cardiovascular Disease Research
- Metabolic Syndrome Studies
- Clinical Biochemistry
Background:
- Hyperhomocysteinemia (HHcy) and hyperlipidemia are independent cardiovascular disease risk factors.
- The relationship between hyperlipidemia and HHcy in hypertensive individuals remains under-investigated.
- Very low-density lipoprotein (VLDL) is a key component of hyperlipidemia.
Purpose of the Study:
- To investigate the association between very low-density lipoprotein (VLDL) and hyperhomocysteinemia (HHcy) in hypertensive patients.
- To determine if VLDL is an independent contributor to HHcy in hypertension.
Main Methods:
- A large cross-sectional study involving 4012 participants from Hunan province, China (July 2013–March 2014).
- Assessment of lipid profiles, homocysteine (Hcy) levels, anthropometrics, blood pressure, and biochemical indicators.
- Statistical analysis including univariate and multivariate logistic regression, adjusting for confounding variables.
Main Results:
- Among 1257 hypertensive participants, 86% had HHcy.
- Higher quartiles of Log VLDL were significantly associated with increased odds of hypertension with HHcy (OR=3.7, P<.001).
- Each unit increase in Log VLDL was associated with a 1.3-fold increased risk of hypertension with HHcy (P<.001), independent of other factors.
Conclusions:
- Log VLDL concentration is an independent risk factor for hypertension associated with HHcy.
- VLDL may serve as a potential diagnostic and prognostic marker for this condition.
- Further research is needed to explore the therapeutic implications of VLDL levels in managing hypertension with HHcy.
Background:
Increasing evidence suggests that hyperhomocysteinemia (HHcy) and hyperlipidemia have been recognized as two independent risks for cardiovascular disease. However, the association between hyperlipidemia and HHcy in hypertensive patients has not been systemically elucidated. The aim of this study was to investigate the relation between very low-density lipoprotein (VLDL) and HHcy in hypertensive patients.
Methods:
From July 2013 to March 2014, a large cross-sectional study was performed using 4012 participants from urban and rural communities in Hunan province, China. Participants underwent accurate assessment of lipid profiles, homocysteine (Hcy), anthropometric, blood pressure, and other biochemical indicators.
Results:
Among 1257 participants with hypertension, 626 (49.80%) were men and 631 (50.20%) were women. In total, 1081 (86.00%) of the participants were found to have HHcy, of which 559 (44.47%) were men and 522 (41.53%) were women. In the univariate analysis, the OR for patients with hypertension associated with hyperhomocysteinemia was significantly enhanced as the quartiles of the Log VLDL were increased. OR for quartile 4 was significantly higher than that for quartile 1 (OR = 3.7, 95% CI: 2.6-5.1; P< .001). Additional adjustment for the confounding variables did not reduce the ORs for the association between the Log VLDL and hypertension associated with hyperhomocysteinemia (OR = 3.8, 95% CI: 2.7-5.5; P< .001; OR = 4.3, 95% CI: 1.6-11.8; P= .004, respectively). We also conducted analyses with Log VLDL as a continuous variable. Each unit increase in the Log VLDL was associated with the 1.3-fold increased risk of hypertension associated with hyperhomocysteinemia (95% CI: 1.9-2.9; P< .001). Adjusting for Cr, TG, TC, and HDL did not affect the relationship.
Conclusions:
Our data indicate that the Log VLDL concentrations appear to be an independent contributor to hypertension associated with hyperhomocysteinemia, even after adjusting for age and other covariables. The utility of the Log VLDL as a diagnostic, prognostic, and therapeutic indicator for the disease warrants further investigation.
Abbreviations:
HHcy: hyperhomocysteinemia; Hcy: homocysteine; VLDL: very low-density lipoprotein; CVD: cardiovascular disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ALT: alanine aminotransferase; Cr: creatinine; UA: uric acid; TG: triglycerides; TC: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FBG: fasting blood glucose; CRP: C-reactive protein; MTHFR: methylene tetrahydrofolate reductase; NO: nitric oxide; HDL-C: high-density lipoprotein cholesterol.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension II: Pathophysiology
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Hypertension IV: Drug Therapy and Lifestyle Modifications

